ac2025 post

a. Elevated serum NfL is diagnostic of MSb. CSF Tau is promising in progressive MSc. NfL and GFAP are promising biomarkers in MS but are non-specific for the disease processd. Well validated proteomics panels can now be used with confidence for clinical decision making in MS

a. CAR-T cells need to be administered intrathecally to enter the CNS.b. Transplantation is preceded by a short course of lymphodepleting chemotherapy.c. Transplantation sometimes is complicated by neurologic adverse effects.d. The technology is rapidly evolvinge. CAR-T transplantation is being tested in both relapsing and progressive MS.

a. Enriched antibodies to EBVb. Tenofovir/emtricitabinec. Allogenic EBV-specific T cellsd. Autologous EBV-specific T cells

a. Perceptronsb. Large language modelsc. Tokensd. Decision trees

a. Dissemination in spaceb. Dissemination in timec. Central vein signd. Optic neuritis

a. Rituximabb. Ofatumumabc. Ocrelizumabd. Ublituximab

a. Relapsing multiple sclerosisb. Non-relapsing secondary progressive multiple sclerosisc. Primary progressive multiple sclerosisd. Radiologically isolated syndrome

AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review updates to McDonald criteria, including new information and how to implement
Review the updated criteria for accurate and differential diagnosis of multiple sclerosis, including MRI imaging, biomarkers, and prognosis
Review the current parameters for MS disease clinical course from prodrome to progression independent of relapse activity (PIRA) and relapse associated worsening (RAW)
Analyze current clinical trial data on the safety, efficacy, and tolerability of current and emerging therapeutic advances for the treatment and repair of multiple sclerosis
Design therapeutic plans to incorporate transition and sequence of treatments, family planning considerations, symptom management, and cognition, including topics for debate, better treatment options for progressive disease, and neuroprotection
Evaluate optimal MS patient comprehensive care utilizing the multi-disciplinary interprofessional team, and patient education
Analyze the recent data and specific healthcare disparities to improve outcomes in all patient populations
Review BTK therapeutics for the management of patients with MS
Develop treatment plans to address the unmet needs of patients with secondary progressive MS
Review and analyze clinical trial data for BTK therapeutics to manage patients with nrSPMS
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD20 in treatment planning
Develop treatment plans to delay disability and progression in patients with RMS
Review and analyze clinical trial data for CD20 therapeutics to manage patients with RMS

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™, 10.0 CNE Contact Hours (Provider #P0491) or 10.0 CPE Contact Hours for participation in the full educational activity.

AMA PRA Category 1 Credit TMCNE Contact Hour, including Pharmacotherapeutic HourCPE Contact Hour (CEUs)Certificate of Participation

AcademicCME thanks you for your participation in this activity.

All information provided improves the scope and purpose of our programs.

EVALUATION FORM